Your browser doesn't support javascript.
loading
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
Piccart, Martine; Procter, Marion; Fumagalli, Debora; de Azambuja, Evandro; Clark, Emma; Ewer, Michael S; Restuccia, Eleonora; Jerusalem, Guy; Dent, Susan; Reaby, Linda; Bonnefoi, Hervé; Krop, Ian; Liu, Tsang-Wu; Pienkowski, Tadeusz; Toi, Masakazu; Wilcken, Nicholas; Andersson, Michael; Im, Young-Hyuck; Tseng, Ling Ming; Lueck, Hans-Joachim; Colleoni, Marco; Monturus, Estefania; Sicoe, Mihaela; Guillaume, Sébastien; Bines, José; Gelber, Richard D; Viale, Giuseppe; Thomssen, Christoph.
Afiliação
  • Piccart M; Institut Jules Bordet and L'Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Procter M; Frontier Science Scotland Ltd, Kincraig, Kingussie, United Kingdom.
  • Fumagalli D; Breast International Group (BIG), Brussels, Belgium.
  • de Azambuja E; Institut Jules Bordet and L'Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Clark E; Roche Products Limited, Welwyn Garden City, United Kingdom.
  • Ewer MS; University of Texas, MD Anderson Cancer Center, Huston, TX.
  • Restuccia E; Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Jerusalem G; CHU Liege and Liege University, Liege, Belgium.
  • Dent S; Duke Cancer Institute, Duke University, Durham, NC.
  • Reaby L; Inaugural Chair-Consumer Advisory Panel, Breast Cancer Trials Group, Newcastle, Australia.
  • Bonnefoi H; Consumer Advisor to Breast Researchers, Garvan Institute of Research, Sydney, Australia.
  • Krop I; Institute Bergonié, UNICANCER, University of Bordeaux, Bordeaux, France.
  • Liu TW; Dana-Farber Cancer Institute, Boston, MA.
  • Pienkowski T; National Health Research Institutes, Taipei, Taiwan.
  • Toi M; Oncological Department, Postgraduate Medical Education Center, Warsaw, Poland.
  • Wilcken N; Breast Cancer Unit, Kyoto University Hospital, Kyoto, Japan.
  • Andersson M; Director of Medical Oncology, Westmead Hospital, Sydney.
  • Im YH; Associate Professor of Medicine, University of Sydney, Sydney, Australia.
  • Tseng LM; Department of Oncology, Rigshospitalet, University Hospital, Copenhagen, Denmark.
  • Lueck HJ; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Colleoni M; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Monturus E; Comprehensive Breast Health Center, Experimental Surgery, Department of Surgery, Taipei-Veterans General Hospital, Taipei, Taiwan.
  • Sicoe M; Gynäkologisch-Onkologische Praxis Hannover, Hannover, Germany.
  • Guillaume S; Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
  • Bines J; Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Gelber RD; Breast International Group (BIG), Brussels, Belgium.
  • Viale G; Institut Jules Bordet and L'Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Thomssen C; Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
J Clin Oncol ; 39(13): 1448-1457, 2021 05 01.
Article em En | MEDLINE | ID: mdl-33539215
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia Adjuvante / Receptor ErbB-2 Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia Adjuvante / Receptor ErbB-2 Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article